Urogen Pharma (NASDAQ:URGN) Posts Earnings Results, Misses Expectations By $0.02 EPS

Urogen Pharma (NASDAQ:URGN) released its earnings results on Wednesday. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02), FiscalAI reports. The company had revenue of $72.46 million during the quarter, compared to analysts’ expectations of $63.55 million.

Here are the key takeaways from Urogen Pharma’s conference call:

• ZUSDURI revenue reached $50.4 million in Q2, up 73% sequentially, with 1,444 activated accounts, 452 prescribers, and repeat prescribers representing approximately 45% of writers. Community practices accounted for about 55% of utilization, supporting the company’s view that adoption remains in an early growth phase.
• UroGen reported durable ZUSDURI clinical results, with 64.5% of complete responders estimated to remain disease-free at 36 months and median response duration not yet reached. Management said real-world physician experience is increasingly supporting use beyond patients who are poor surgical candidates.
• JELMYTO revenue was stable at $22 million, and the company maintained its 2026 guidance of $97 million to $101 million. However, management has not yet observed a meaningful “reverse halo” effect from the ZUSDURI launch on JELMYTO demand.
• UroGen expects to submit the UGN-103 NDA within weeks, complete UGN-104 enrollment by year-end, and begin a UGN-501 Phase I study later in 2026. A patent allowance covering ZUSDURI and UGN-103 is expected to provide protection through July 2044.
• Full-year operating expense guidance increased to $260 million-$270 million as UroGen accelerates ZUSDURI promotional and patient-awareness spending and advances pipeline programs. Management remains confident it can reach profitability with existing capital resources, but the higher investment is expected to pressure near-term results.

Urogen Pharma Price Performance

NASDAQ:URGN traded down $0.12 during trading hours on Thursday, reaching $46.31. The company had a trading volume of 808,488 shares, compared to its average volume of 795,447. Urogen Pharma has a 1-year low of $15.86 and a 1-year high of $48.03. The firm has a market cap of $2.26 billion, a PE ratio of -16.75 and a beta of 1.57. The business’s 50 day moving average price is $35.73 and its 200-day moving average price is $26.80.

Analyst Ratings Changes

Several analysts have weighed in on URGN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Friday, July 17th. Jefferies Financial Group raised Urogen Pharma to a “strong-buy” rating in a report on Friday, April 24th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $44.00 target price on shares of Urogen Pharma in a research report on Wednesday, July 15th. Guggenheim increased their price target on shares of Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday. Finally, UBS Group reissued a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $48.78.

Trending Headlines about Urogen Pharma

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: HC Wainwright raised its price target from $45 to $75 and initiated or reaffirmed a “Buy” rating. The new target implies approximately 60.7% upside from the referenced share price, signaling increased confidence in UroGen’s commercial outlook. Benzinga
• Positive Sentiment: Second-quarter revenue reached $72.46 million, exceeding analyst estimates of $63.55 million. ZUSDURI generated $50.4 million in revenue, highlighting continued commercial traction for the company’s key product. UroGen second-quarter results
• Positive Sentiment: The quarterly loss narrowed substantially to $0.28 per share from a $1.05 loss a year earlier, suggesting improving operating leverage even though the company remains unprofitable. Zacks earnings report
• Neutral Sentiment: Management discussed the quarter and business outlook during the Q2 earnings call, which investors may review for additional details on ZUSDURI’s launch, commercial execution and future growth plans. Q2 2026 earnings call transcript
• Negative Sentiment: UroGen still posted a quarterly loss. Depending on the estimate set used, the $0.28 per-share loss was either better than the $0.38 consensus cited by Zacks or slightly below the $0.26 estimate cited elsewhere, creating a mixed earnings signal. UroGen earnings report

Insider Activity at Urogen Pharma

In other news, insider Mark Schoenberg sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the sale, the insider owned 119,763 shares of the company’s stock, valued at $4,790,520. This trade represents a 7.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 25,222 shares of company stock worth $892,661. 4.80% of the stock is owned by company insiders.

Institutional Trading of Urogen Pharma

A number of hedge funds have recently added to or reduced their stakes in URGN. Invesco Ltd. increased its holdings in Urogen Pharma by 21.1% in the fourth quarter. Invesco Ltd. now owns 27,066 shares of the company’s stock valued at $634,000 after buying an additional 4,711 shares in the last quarter. Susquehanna Portfolio Strategies LLC purchased a new position in shares of Urogen Pharma in the 4th quarter valued at about $641,000. Superstring Capital Management LP raised its holdings in Urogen Pharma by 717.1% in the 4th quarter. Superstring Capital Management LP now owns 718,354 shares of the company’s stock worth $16,824,000 after purchasing an additional 630,442 shares during the period. Orbimed Advisors LLC raised its holdings in Urogen Pharma by 27.1% in the 4th quarter. Orbimed Advisors LLC now owns 875,487 shares of the company’s stock worth $20,504,000 after purchasing an additional 186,487 shares during the period. Finally, Opaleye Management Inc. purchased a new position in Urogen Pharma during the fourth quarter worth approximately $6,286,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.